Working On The Tough Cases: Mayo Clinic Cancer Center

... Mayo Clinic Cancer Center, in collaboration with researchers from the University of Iowa, have presented results of a Phase II clinical study indicating that an oral drug, tipifarnib, can stall or reverse disease progression for patients with relapsed aggressive non-Hodgkin lymphoma. Lead researcher and Mayo Clinic hematologist Thomas Witzig, M.D. [click link for full article] ...